Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Type 1 diabetes
- Arresting T1D: Why is it so difficult?
- Arresting T1D: What have we learned? (1)
- Aspecific immune modulation
- Arguments for an immune-basis for T1D
- How are beta-cells destroyed in T1D?
- Natural history of T1D
- Genetic predisposition: Driven by MHC
- Time trends in incidence of T1D
- Putative triggers
- Natural history of T1D: Summary
- Environmental triggers as therapeutic targets
- Arresting T1D: What have we learned? (2)
- Immune modulatory studies in man (1)
- Short-term immune modulation
- Immune modulatory studies in man (2)
- ATG & Anti-CD3 targets
- NOD mouse
- ATG
- Low dose ATG & ATG/G-CSF (1)
- Low dose ATG & ATG/G-CSF (2)
- Adverse events of ATG & ATG/G-CSF treatment
- Low dose ATG & ATG/G-CSF at 24-months
- Anti-CD3 Abs provide temporary protection
- Anti-CD3 in family members of people with T1D
- Arresting T1D: what have we learned? (3)
- T1D is a heterogeneous disease
- Quality of insulitis differs by age
- ABATE study
- Arresting T1D: What have we learned? (4)
- Antigen-specific tolerance induction
- Antigen-specific studies in man
- Oral insulin does not prevent T1D in humans
- Late intervention in NOD mice
- Lactococcus lactis
- Experimental design
- Reversal of diabetes
- Other combinations of therapies
- Arresting T1D: What have we learned? (5)
- INNODIA
- INNODIA: Biomarker analysis
- Arresting T1D: What have we learned? (6)
- Thank you
Topics Covered
- Etiology of type 1 diabetes
- Clinical stages of type 1 diabetes
- Genetic predisposition
- Environmental triggers
- Obstacles on the path to prevention
- Heterogeneity in disease progression
- Role of the immune system
- Role of the beta-cell in its own destruction
- Dialogue between the beta-cell and the immune system
- Biomarkers of disease progression or therapeutic success
- Animal models for type 1 diabetes and their issues
- Promising clinical interventions
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Mathieu, C. (2021, July 28). Prevention of type 1 diabetes [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/SCQV9047.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Chantal Mathieu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to this lecture on "Prevention of Type 1 Diabetes".
My name.
Is Chantal Mathieu.
I'm the Head of Endocrinology at the University Hospital Gasthuisberg and
Professor of Medicine at the University of Leuven in Leuven Belgium.
0:17
In this lecture, we will discuss the obstacles to prevention of Type 1 diabetes,
but also the lessons learned from basic research and clinical trials.
0:29
Type 1 diabetes is quite a rare form of diabetes
affecting about five percent of all people living with diabetes.
This characterized by insulin deficiency and
thus insulin treatment is needed for survival.
Type 1 diabetes typically affects children and young people,
but can also occur in adults.
We as clinicians talk about Type 1 diabetes when
signs and symptoms of hyperglycemia are present in
an individual where we also can find signs of autoimmune attack
of the insulin producing beta-cells in the islets of Langerhans in the pancreas.
This is reflected very often by the presence of autoantibodies.
We have also, however,
discovered that Type 1 diabetes is present many months,
even many years before we find the clinical signs of hyperglycemia.
Therefore we have redefined Type 1 diabetes in different stages.
The clinical stage being stage 4.
Stage 3 is when individuals have abnormal glucose tolerance when we challenge
them with an oral glucose tolerance test and have already autoantibodies present.
Stage 2 is when individuals still have
enough beta-cells to maintain normal glucose tolerance,
but also have signs of autoimmunity as demonstrated by the presence of autoantibodies.
We also have now stage 1,
which is the stage where we know that there is a predisposition for Type 1 diabetes,
but autoimmunity has not started yet.
So when talking about prevention,
we can define different stages of prevention.
Indeed, we can talk about prevention when preventing
the progression of an abnormal glucose tolerance to avert Type 1 diabetes.
We can also talk about prevention or arrest when
preventing going from a normal glucose tolerance to an abnormal glucose tolerance.
We even can talk about prevention when we want to prevent autoimmunity altogether.